Alzheimer's disease: Brain expression of a metabolic disorder?

Trends in Endocrinology and Metabolism

Volumn 21, Issue 9, 2010, Pages 537-544

  Merlo, Sara ^a   Spampinato, Simona ^a   Canonico, Pier Luigi ^b   Copani, Agata ^a   Sortino, Maria Angela ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN E; CHOLESTEROL; LEPTIN;

ALZHEIMER DISEASE; DYSLIPIDEMIA; HUMAN; METABOLIC DISORDER; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; ANIMALS; BRAIN; HUMANS; LIPID METABOLISM;

EID: 77956183954     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2010.05.005     Document Type: Review

References (90)

1. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
2. Kim J., et al. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009, 63:287-303.
3. Sleegers K., et al. The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. Trends Genet. 2010, 26:84-93.
4. van Es M.A., van den Berg L.H. Alzheimer's disease beyond APOE. Nat. Genet. 2009, 41:1047-1048.
5. Pimplikar S.W. Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int. J. Biochem. Cell Biol. 2009, 41:1261-1268.
6. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch. Neurol. 2009, 66:300-305.
7. Loy C.T., Twigg S.M. Growth factors, AGEing, and the diabetes link in Alzheimer's disease. J. Alzheimers Dis. 2009, 16:823-831.
8. Luchsinger J.A. Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective. Eur. J. Pharmacol. 2008, 585:119-129.
9. de la Monte S.M. Insulin resistance and Alzheimer's disease. BMB Rep. 2009, 42:475-481.
10. Whitmer R.A., et al. Central obesity and increased risk of dementia more than three decades later. Neurology 2008, 71:1057-1064.
11. Stewart R., et al. A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study. Arch. Neurol. 2005, 62:55-60.
12. Atti A.R., et al. Late-life body mass index and dementia incidence: nine-year follow-up data from the Kungsholmen Project. J. Am. Geriatr. Soc. 2008, 56:111-116.
13. Buchman A.S., et al. Change in body mass index and risk of incident Alzheimer disease. Neurology 2005, 65:892-897.
14. Smith C.C., et al. Native and oxidized low-density lipoproteins modulate the vasoactive actions of soluble beta-amyloid peptides in rat aorta. Clin. Sci. (Lond) 2007, 113:427-434.
15. Patil S., Chan C. Palmitic and stearic fatty acids induce Alzheimer-like hyperphosphorylation of tau in primary rat cortical neurons. Neurosci. Lett. 2005, 384:288-293.
16. Blain J.F., et al. A polymorphism in lipoprotein lipase affects the severity of Alzheimer's disease pathophysiology. Eur. J. Neurosci. 2006, 24:1245-1251.
17. Paradis E., et al. Lipoprotein lipase and endothelial lipase expression in mouse brain: regional distribution and selective induction following kainic acid-induced lesion and focal cerebral ischemia. Neurobiol. Dis. 2004, 15:312-325.
18. Martins I.J., et al. Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. J. Neurochem. 2009, 111:1275-1308.
19. Dietschy J.M., Turley S.D. Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 2001, 12:105-112.
20. Pfrieger F.W. Cholesterol homeostasis and function in neurons of the central nervous system. Cell. Mol. Life Sci. 2003, 60:1158-1171.
21. Mason R.P., et al. Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. Neurobiol. Aging 1992, 13:413-419.
22. Ledesma M.D., Dotti C.G. Amyloid excess in Alzheimer's disease: what is cholesterol to be blamed for?. FEBS Lett. 2006, 580:5525-5532.
23. Ledesma M.D., et al. Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains. EMBO Rep. 2003, 4:1190-1196.
24. Shobab L.A., et al. Cholesterol in Alzheimer's disease. Lancet Neurol. 2005, 4:841-852.
25. Stefani M., Liguri G. Cholesterol in Alzheimer's disease: unresolved questions. Curr. Alzheimer Res. 2009, 6:15-29.
26. Wolozin B. Cholesterol and the biology of Alzheimer's disease. Neuron 2004, 41:7-10.
27. Cordy J.M., et al. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:11735-11740.
28. Wahrle S., et al. Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol. Dis. 2002, 9:11-23.
29. Kojro E., et al. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:5815-5820.
30. Grimm M.O., et al. Amyloid beta as a regulator of lipid homeostasis. Trends Mol. Med. 2007, 13:337-344.
31. Eckert G.P., et al. Statins: drugs for Alzheimer's disease?. J. Neural Transm. 2005, 112:1057-1071.
32. Fassbender K., et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:5856-5861.
33. Petanceska S.S., et al. Statin therapy for Alzheimer's disease: will it work?. J. Mol. Neurosci. 2002, 19:155-161.
34. Refolo L.M., et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2001, 8:890-899.
35. Friedhoff L.T., et al. Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide. Int. J. Neuropsychopharmacol. 2001, 4:127-130.
36. Mamo J.C., et al. Plasma lipoprotein beta-amyloid in subjects with Alzheimer's disease or mild cognitive impairment. Ann. Clin. Biochem. 2008, 45:395-403.
37. Wolozin B., et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 2000, 57:1439-1443.
38. Caballero J., Nahata M. Do statins slow down Alzheimer's disease? A review. J. Clin. Pharm. Ther. 2004, 29:209-213.
39. Sparks D.L., et al. Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. Curr. Alzheimer Res. 2005, 2:343-353.
40. Ostrowski S.M., et al. Statins reduce amyloid-beta production through inhibition of protein isoprenylation. J. Biol. Chem. 2007, 282:26832-26844.
41. Zhou Y., et al. Geranylgeranyl pyrophosphate stimulates gamma-secretase to increase the generation of Abeta and APP-CTFgamma. FASEB J. 2008, 22:47-54.
42. Puglielli L., et al. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat. Cell Biol. 2001, 3:905-912.
43. Hutter-Paier B., et al. The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease. Neuron 2004, 44:227-238.
44. Wollmer M.A., et al. Genetic association of acyl-coenzyme A: cholesterol acyltransferase with cerebrospinal fluid cholesterol levels, brain amyloid load, and risk for Alzheimer's disease. Mol. Psychiatry 2003, 8:635-638.
45. Bryleva E.Y., et al. ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:3081-3086.
46. Hudry E., et al. Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. Mol. Ther. 2010, 18:44-53.
47. Papassotiropoulos A., et al. Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch. Neurol. 2003, 60:29-35.
48. Borroni B., et al. Intronic CYP46 polymorphism along with APOE genotype in sporadic Alzheimer disease: from risk factors to disease modulators. Neurobiol. Aging 2004, 25:747-751.
49. van Meer G., et al. ABC lipid transporters: extruders, flippases, or flopless activators?. FEBS Lett. 2006, 580:1171-1177.
50. Zelcer N., et al. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:10601-10606.
51. Jiang Q., et al. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008, 58:681-693.
52. Riddell D.R., et al. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol. Cell. Neurosci. 2007, 34:621-628.
53. Koldamova R., et al. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J. Biol. Chem. 2005, 280:43224-43235.
54. Wahrle S.E., et al. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J. Biol. Chem. 2005, 280:43236-43242.
55. Wahrle S.E., et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J. Clin. Invest. 2008, 118:671-682.
56. Katzov H., et al. Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism. Hum. Mutat. 2004, 23:358-367.
57. Fagan A.M., Holtzman D.M. Astrocyte lipoproteins, effects of apoE on neuronal function, and role of apoE in amyloid-beta deposition in vivo. Microsc. Res. Tech. 2000, 50:297-304.
58. Cao D., et al. Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. Neurobiol. Aging 2006, 27:1632-1643.
59. Burns M.P., et al. Co-localization of cholesterol, apolipoprotein E and fibrillar Abeta in amyloid plaques. Brain Res. Mol. Brain Res. 2003, 110:119-125.
60. Tokuda T., et al. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Biochem. J. 2000, 348:359-365.
61. Corder E.H., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
62. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 2009, 10:333-344.
63. Castano E.M., et al. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochem. J. 1995, 306:599-604.
64. Bell R.D., et al. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J. Cereb. Blood Flow Metab. 2007, 27:909-918.
65. Deane R., et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest. 2008, 118:4002-4013.
66. Koistinaho M., et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat. Med. 2004, 10:719-726.
67. Bales K.R., et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 1997, 17:263-264.
68. Schwartz M.W., et al. Central nervous system control of food intake. Nature 2000, 404:661-671.
69. Dietrich M.O., et al. Megalin mediates the transport of leptin across the blood-CSF barrier. Neurobiol. Aging 2008, 29:902-912.
70. Hegyi K., et al. Leptin-induced signal transduction pathways. Cell Biol. Int. 2004, 28:159-169.
71. Scott M.M., et al. Leptin targets in the mouse brain. J. Comp. Neurol. 2009, 514:518-532.
72. Long Y.C., Zierath J.R. AMP-activated protein kinase signaling in metabolic regulation. J. Clin. Invest. 2006, 116:1776-1783.
73. Guo Z., et al. Leptin-mediated cell survival signaling in hippocampal neurons mediated by JAK STAT3 and mitochondrial stabilization. J. Biol. Chem. 2008, 283:1754-1763.
74. Shanley L.J., et al. Leptin enhances NMDA receptor function and modulates hippocampal synaptic plasticity. J. Neurosci. 2001, 21:RC186.
75. Walker C.D., et al. Long-lasting effects of elevated neonatal leptin on rat hippocampal function, synaptic proteins and NMDA receptor subunits. J. Neurosci. Res. 2007, 85:816-828.
76. Li X.L., et al. Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents. Neuroscience 2002, 113:607-615.
77. Farr S.A., et al. Effects of leptin on memory processing. Peptides 2006, 27:1420-1425.
78. Garza J.C., et al. Leptin increases adult hippocampal neurogenesis in vivo and in vitro. J. Biol. Chem. 2008, 283:18238-18247.
79. Holden K.F., et al. Serum leptin level and cognition in the elderly: Findings from the Health ABC Study. Neurobiol. Aging 2009, 30:1483-1489.
80. Lieb W., et al. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA 2009, 302:2565-2572.
81. Fewlass D.C., et al. Obesity-related leptin regulates Alzheimer's Abeta. FASEB J. 2004, 18:1870-1878.
82. Tezapsidis N., et al. Leptin: a novel therapeutic strategy for Alzheimer's disease. J. Alzheimers Dis. 2009, 16:731-740.
83. Greco S.J., et al. Chronic leptin supplementation ameliorates pathology and improves cognitive performance in a transgenic mouse model of Alzheimer's disease. J. Alzheimers Dis. 2009, 10.3233/JAD-2009-1308.
84. Greco S.J., et al. Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells. Neurosci. Lett. 2009, 455:191-194.
85. Greco S.J., et al. Leptin reduces Alzheimer's disease-related tau phosphorylation in neuronal cells. Biochem. Biophys. Res. Commun. 2008, 376:536-541.
86. Greco S.J., et al. Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells. Biochem. Biophys. Res. Commun. 2009, 380:98-104.
87. Signore A.P., et al. Leptin neuroprotection in the CNS: mechanisms and therapeutic potentials. J. Neurochem. 2008, 106:1977-1990.
88. Golde T.E., et al. Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp. Neurol. 2010, 223:252-266.
89. Jolivalt C.G., et al. Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J. Neurosci. Res. 2008, 86:3265-3274.
90. Farris W., et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4162-4167.